Loading data for LFCR — first visit, this takes a few seconds.

알림

Lifecore Biomedical Inc. (LFCR)

NasdaqGS: LFCR · 실시간 가격 · USD

4.77

-0.06 (-1.24%)

종가 기준: Aug 19, 2026, 8:00 PM

-1.24% (1D)

데이터 없음

매수호가	3.46
시가총액	168.82M
매출 (ttm)	129.46M
순이익 (ttm)	-34.5M
베타	1.09
EPS (ttm)	-1.29
P/E (ttm)	n/a
선행 P/E	-5.72
P/B (ttm)	-4.93
P/S (ttm)	1.30
Earnings Date	Nov 3, 2026

매도호가	6.15
거래량	89,551
평균 거래량 (20일)	194,082
시가	4.83
전일 종가	4.83
일중 범위	4.71 - 4.97
52주 범위	3.63 - 8.98
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

LFCR 소개

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in vari...

섹터 Healthcare

IPO 일자 Feb 15, 1996

직원 수 382

상장 거래소 NasdaqGS

티커 LFCR

웹사이트 https://www.lifecore.com

전체 기업 정보

재무 실적

2025년 Lifecore Biomedical의 매출은 128.87M로, 전년 128.26M 대비 0.47% 증가했습니다. 순이익은 -38.72M로, -422.29% 감소했습니다.

재무제표

어닝 서프라이즈

Lifecore Biomedical가 Aug 5, 2026에 분기 실적을 발표했습니다:

매출 $34.17M 예상치 하회 $0, 및 -2.81% 전년 대비 감소.

EPS -0.19 예상치 상회 0.03, 및 5.00% 전년 대비 성장.

다음 실적 발표

Lifecore Biomedical Inc.의 실적 발표 예정일은 Nov 3, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · Motley Fool

Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript

Customer demand inflection expected in 2027 despite Q2 revenue decline.

1주 전 · Moby

Lifecore Biomedical, Inc. Q2 2026 Earnings Call Summary

Moby summary of Lifecore Biomedical, Inc.'s Q2 2026 earnings call

2주 전 · GuruFocus.com

Lifecore Biomedical Inc (LFCR) (Q2 2026) Earnings Call Highlights: Strategic Wins and Capacity ...

Despite a 6.2% revenue dip, Lifecore secures nine new programs and reaffirms 2026 guidance, positioning for a 200% demand surge from its largest customer by 2028.

2주 전 · MarketBeat

Lifecore Biomedical Q2 Earnings Call Highlights

Lifecore Biomedical (NASDAQ:LFCR) reaffirmed its 2026 revenue and adjusted EBITDA guidance while outlining plans to support sharply higher fill-finish demand from its largest customer beginning in 202...

1개월 전 · Insider Monkey

Lifecore Biomedical Inc (LFCR) Continues Winning Contracts, Ignored by the Market

Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for t...

2 페이지 중 1

Lifecore Biomedical Inc. (LFCR)